Holen Sie sich die Stockscreener-App
16.21
2.41%
-0.40
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Amgen Inc (AMGN-Q) QuotePress Release - The Globe and Mail
Should You Scoop Up This 'Strong Buy' Biotech Before December 23? - Inkl
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowShould You Sell? - MarketBeat
Newly Public Biotech Startup Hires Life Sciences Veteran as GC - Law.com
Upstream Bio (NASDAQ:UPB) Shares Gap DownWhat's Next? - MarketBeat
Upstream Bio Appoints Allison Ambrose as General Counsel - citybiz
Upstream Bio (NASDAQ:UPB) Shares Down 5%Time to Sell? - MarketBeat
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation (UPB) - Seeking Alpha
Upstream Bio To Be Added To Russell 2000 - MENAFN.COM
Upstream Bio to be Added to Russell 2000 - Baystreet.ca
Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewswire
Upstream Bio to Join Russell 2000® Index, Gaining Access to $10.5T Benchmark-Linked Assets - StockTitan
Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry (NASDAQ:UPB) - Seeking Alpha
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Upstream Bioprocessing Market to Reach USD 82.10 Billion by 2032 from USD 22.79 Billion in 2023 | CAGR of 15.35% - GlobeNewswire
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Upstream Bio CEO to Present at Piper Sandler Healthcare Conference Dec 3 | UPB Stock News - StockTitan
Upstream Bioprocessing Industry Analysis and Forecast, - GlobeNewswire
Upstream Bio, Inc.’s (NASDAQ:UPB) Quiet Period Set To End on November 20th - Defense World
Upstream Bio, Inc.'s (NASDAQ:UPB) Quiet Period Set To End on November 20th - MarketBeat
Brokers Set Expectations for Upstream Bio Q4 Earnings - MarketBeat
Upstream Bio Advances Clinical Trials, Strengthens Financials - TipRanks
Tezspire Phase III Nasal Polyp Data May Lead To Second Indication - Scrip
William Blair Weighs in on Upstream Bio Q4 Earnings - Defense World
Upstream Bio Inc (UPB) Quarterly 10-Q Report - Quartz
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
FMR LLC Acquires New Stake in Upstream Bio Inc - GuruFocus.com
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Upstream Bio initiated with an Overweight at Piper Sandler - MSN
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MarketBeat
Here are Tuesday's biggest analyst calls: Apple, Microsoft, Palantir, Eli Lilly, Broadcom, Krispy Kreme, Live Nation & more - Head Topics
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
Upstream Bio initiated with an Overweight at JPMorgan - MSN
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Piper Sandler Begins Coverage on Upstream Bio (NASDAQ:UPB) - MarketBeat
TD Cowen bullish on Upstream Bio, bets on differentiated asthma treatment verekitug - Investing.com
Piper Sandler sees big potential for Upstream Bio asthma therapy, Overweight on stock - Investing.com UK
Upstream Bio prices IPO at $17 per share - MSN
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline News & Insights
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
Goldman-backed drug developer Septerna raises $288 mln in US IPO - Reuters.com
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Upstream Bio stock rallies 32% following upsized $255M IPO - MSN
Upstream Bioprocessing Market Forecast 2024: Key Global Developments - openPR
Upstream Bio Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Upstream Bio Rings the Opening Bell - Nasdaq
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):